Insmed, Inc. (INSM) – What Are Investment Firms Thinking About This Stock?

Insmed, Inc. (NASDAQ:INSM – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twenty-three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $196.52.

A number of brokerages recently issued reports on INSM. Benchmark reiterated a “buy” rating on shares of Insmed in a report on Monday, November 2nd. Roth Capital reissued a “buy” rating and issued a $198.00 price target (down from $212.00) on shares of Insmed in a research report on Tuesday, September 15th. The Goldman Sachs Group started coverage on shares of Insmed in a research note on Thursday, September 24th. They set a “buy” rating and a $188.00 price target for the company. Raymond James Financial set a $173.00 price objective on shares of Insmed in a report on Tuesday, October 20th. Finally, Barclays dropped their price objective on shares of Insmed from $237.00 to $207.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 30th.

Get Our Latest Stock Analysis on INSM

Insmed Price Performance

INSM stock opened at $119.80 on Friday. The stock’s 50 day simple moving average is $110.51 and its 200 day simple moving average is $122.84. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75.

Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The firm had revenue of $524.43 million during the quarter, compared to analyst estimates of $500.36 million. Insmed had a negative net margin of 39.85% and a negative return on equity of 96.38%. The company’s revenue was up 268.4% on a year-over-year basis. During the same period last year, the business posted ($1.75) EPS. Equities research analysts forecast that Insmed will post -1.86 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, Director David Brennan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company’s stock, valued at $4,865,512. The trade was a 38.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Insmed

Hedge funds have recently added to or reduced their stakes in the stock. Coastal Bridge Advisors LLC bought a new stake in Insmed during the 3rd quarter worth approximately $470,000. Integrated Wealth Concepts LLC raised its stake in shares of Insmed by 852.8% in the third quarter. Integrated Wealth Concepts LLC now owns 10,547 shares of the biopharmaceutical company’s stock worth $1,204,000 after purchasing an additional 9,440 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund bought a new position in shares of Insmed in the third quarter valued at approximately $624,000. Kentucky Retirement Systems bought a new position in shares of Insmed in the third quarter valued at approximately $1,541,000. Finally, Algert Global LLC lifted its holdings in shares of Insmed by 77.8% in the third quarter. Algert Global LLC now owns 70,185 shares of the biopharmaceutical company’s stock valued at $8,011,000 after purchasing an additional 30,705 shares in the last quarter.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

Featured Stories

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.